Pharmaceuticals Company Releases Positive Preclinical Study Data For Neurological Disorder Treatment

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a pre-clinical-stage pharmaceutical company, has recently announced new insights from additional preclinical study data regarding the mechanism of action and toxicology of its novel oral ketamine analog, Ketamir-2. This latest development marks progress in the company's goal of submitting an Investigational New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Ketamir-2 later this year. $MIRA Pharmaceuticals(MIRA.US)$